Scientists worldwide are fighting to contain the ongoing COVID-19 pandemic, which has already claimed more than 2.48 million lives. Preventing spillback infections is essential to containing the pandemic. To do so, it is vital to understand the nature of the virus, i.e., its susceptibility to a range of hosts.
Corticosteroid receptor inhibitor shows anti-SARS-CoV-2 activity in vivo
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To date, SARS-CoV-2 has infected over 112 million people and has been responsible for over 2.48 million deaths.
While vaccines against SARS-CoV-2 are being administered globally, treatment options for those infected are still limited. A team of researchers examined PT150, which is an allosteric modulator of androgen and glucocorticoid receptors, to assess whether it had any antiviral activity or immunomodulatory activity to decrease the hyperinflammatory response of SARS-CoV-2 infection.
The researchers demonstrated PT150 as an effective inhibitor of SARS-CoV-2 infection in the Syrian golden hamster model. They found that oral PT150 given once daily for seven days prevented replication of SARS-CoV-2 in the lungs, decreased infiltration of macrophages, improved lung pathology
In Vivo Probes for Detecting Inflammation Markers in Humans and Animals
Thought LeadersProf. Parastoo HashemiSenior Lecturer in Bioengineering, Imperial London College
Associate Professor of Chemistry, University of South Carolina
In this interview, News-Medical Life Sciences talks to Parry Hashemi about the research on in vivo probes for detecting inflammation markers in humans and animals that she will present at Pittcon.
What are some traditional methods for detecting inflammation markers in humans and animals?
Traditionally, a blood or plasma sample will be taken. There are certain proteins that indicate an inflammation; for example, pro-inflammatory cytokines. If the levels of these are raised that corresponds to inflammation.
Bioline Agrosciences (InVivo) Acquires Dudutech (Kenya) and Reaffirms its Global Ambitions in Biocontrol
Bioline Agrosciences (InVivo Group) announces the acquisition of the Kenyan Biocontrol Company
Dudutech from the British Company
Flamingo Group International (a World Leader in the production and sale of Cut Flowers & Plants and Fresh Vegetables). The acquisition of Dudutech marks an important step for Bioline Agrosciences, which is becoming de facto a world-class player in the production and distribution of biocontrol solutions.
For
CEO of InVivo group, this acquisition is a huge step for Bioline, our agricultural subsidiary, which is becoming a major player in biocontrol at the international level. It s perfectly aligned with our vision to promote the agricultural and food transition towards a resilient agrosystem, by deploying innovative and responsible solutions and products.
New isolated lymphatic vessel lumen perfusion system to evaluate nanoparticle dynamics
Nanoparticles used in drug delivery systems, bioimaging, and regenerative medicine migrate from tissues to lymphatic vessels after entering the body, so it is necessary to clarify the interaction between nanoparticles and lymphatic vessels. Although technology to observe the flow of nanoparticles through lymphatic vessels in vivo has been developed, there has been no method to evaluate the flow of nanoparticles in a more detailed and quantitative manner ex vivo.
Thus, research was conducted to develop an ex vivo lymphatic vessel lumen perfusion system to determine how nanoparticles move in lymphatic vessels and how they affect the physiological movement of lymphatic vessels.